Pfizer in Schizophrenia Deal With Taisho (Japan)
This article was originally published in PharmAsia News
Executive Summary
Japanese drug company Taisho Pharmaceutical has entered negotiations to outlicense an experimental schizophrenia drug to the world's biggest pharmaceutical company, Pfizer. If the deal goes through, Taisho will receive a $22 million upfront payment. Pfizer would then gain development and marketing rights for the drug outside of Japan. Depending on the drug's progress, Taisho could then receive a number of development and milestone payments. (Click here for more